Source: http://www.google.com/patents/US8084414?dq=inventor:%22Arthur+R.+Hair%22
Timestamp: 2017-05-25 11:40:57
Document Index: 448054492

Matched Legal Cases: ['§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 41', '§ 1', '§ 1', '§ 311', '§ 304', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1', '§ 1']

Patent US8084414 - Methods involving long lasting synthetic exendin-4-peptide conjugates - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsModified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may...http://www.google.com/patents/US8084414?utm_source=gb-gplus-sharePatent US8084414 - Methods involving long lasting synthetic exendin-4-peptide conjugatesAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS8084414 B2Publication typeGrantApplication numberUS 11/215,967Publication dateDec 27, 2011Filing dateAug 30, 2005Priority dateMay 17, 1999Fee statusLapsedAlso published asUS6514500, US6821949, US6887849, US8080516, US8093206, US20030108567, US20030108568, US20040127398, US20040138100, US20060009377, US20060058235, US20060135426, US20090075890Publication number11215967, 215967, US 8084414 B2, US 8084414B2, US-B2-8084414, US8084414 B2, US8084414B2InventorsDominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. PierreOriginal AssigneeConjuchem, LlcExport CitationBiBTeX, EndNote, RefManPatent Citations (115), Non-Patent Citations (149), Classifications (18), Legal Events (8) External Links: USPTO, USPTO Assignment, EspacenetMethods involving long lasting synthetic exendin-4-peptide conjugates
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4462941Jun 10, 1982Jul 31, 1984The Regents Of The University Of CaliforniaDynorphin amide analogsUS4766106Jan 25, 1988Aug 23, 1988Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugationUS5118666Jun 1, 1990Jun 2, 1992The General Hospital CorporationInsulinotropic hormoneUS5120712Jun 1, 1990Jun 9, 1992The General Hospital CorporationInsulinotropic hormoneUS5149782Aug 19, 1988Sep 22, 1992Tanox Biosystems, Inc.Molecular conjugates containing cell membrane-blending agentsUS5274075Apr 27, 1990Dec 28, 1993Tanox Biosystems, Inc.Newly identified human epsilon immunoglobulin peptides and related productsUS5424286May 24, 1993Jun 13, 1995Eng; JohnExendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising sameUS5493007Sep 23, 1994Feb 20, 1996Genentech, Inc.Platelet aggregation inhibitors having high specificity for GPIIBIIIAUS5545618Dec 10, 1993Aug 13, 1996Buckley; Douglas I.GLP-1 analogs useful for diabetes treatmentUS5574008Aug 30, 1994Nov 12, 1996Eli Lilly And CompanyBiologically active fragments of glucagon-like insulinotropic peptideUS5580853Mar 22, 1994Dec 3, 1996New England Deaconess HospitalModified polypeptides with increased biological activityUS5612034May 3, 1994Mar 18, 1997Redcell, Inc.Super-globuling for in vivo extended lifetimesUS5612458Dec 22, 1994Mar 18, 1997Dako/AsAntibody to PNA/nucleic acid complexesUS5614487May 28, 1993Mar 25, 1997Genentech, Inc.Sustained release pharmaceutical compositionUS5614492Nov 23, 1993Mar 25, 1997The General Hospital CorporationInsulinotropic hormone GLP-1 (7-36) and uses thereofUS5654276Jun 7, 1995Aug 5, 1997Affymax Technologies N.V.Peptides and compounds that bind to the IL-5 receptorUS5770570Aug 25, 1995Jun 23, 1998Paul; SudhirMethod of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptideUS5840733Jul 1, 1996Nov 24, 1998Redcell, Canada, Inc.Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimesUS5843440Aug 14, 1996Dec 1, 1998Redcell Canada, Inc.Cellular and serum protein anchors for modulating pharmacokineticsUS5942620Jul 1, 1998Aug 24, 1999Conjuchem, Inc.Methods for producing novel conjugates of thrombin inhibitorsUS5958909Nov 20, 1996Sep 28, 1999The General Hospital CorporationInsulinotropic hormones and uses thereofUS5981488Mar 25, 1998Nov 9, 1999Eli Lillly And CompanyGlucagon-like peptide-1 analogsUS6087375Jun 11, 1999Jul 11, 2000Conjuchem, Inc.Methods of treating or preventing thrombosesUS6103233Jun 7, 1995Aug 15, 2000Conjuchem, Inc.Cellular and serum protein anchors and conjugatesUS6107489Mar 12, 1999Aug 22, 2000Conjuchem, Inc.Extended lifetimes in vivo renin inhibitorsUS6133235Jul 6, 1999Oct 17, 2000Eli Lilly And CompanyGlucagon-like insulinotropic peptides compositions and methodsUS6191102Oct 30, 1997Feb 20, 2001Eli Lilly And CompanyUse of GLP-1 analogs and derivatives administered peripherally in regulation of obesityUS6197332Aug 12, 1998Mar 6, 2001Chiron CorporationLipid-conjugated polyamide compounds and related compositions and methods thereofUS6277583Feb 7, 1996Aug 21, 2001Conjuchem, Inc.Affinity labeling libraries and applications thereofUS6277863Jun 22, 2000Aug 21, 2001Conjuchem, Inc.Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimesUS6284725Apr 30, 1999Sep 4, 2001Bionebraska, Inc.Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissueUS6329336May 17, 2000Dec 11, 2001Conjuchem, Inc.Long lasting insulinotropic peptidesUS6403324Mar 13, 1998Jun 11, 2002Conjuchem, Inc.Affinity labeling libraries with tagged leaving groupUS6437092Nov 6, 1998Aug 20, 2002Conjuchem, Inc.Conjugates of opioids and endogenous carriersUS6440417Nov 5, 1999Aug 27, 2002Conjuchem, Inc.Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatmentsUS6451974Mar 13, 2000Sep 17, 2002Novo Nordisk A/SMethod of acylating peptides and novel acylating agentsUS6500918Mar 1, 2001Dec 31, 2002Conjuchem, Inc.Conjugate comprising an antinociceptive agent covalently bonded to a blood componentUS6506724Jun 1, 1999Jan 14, 2003Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the treatment of gestational diabetes mellitusUS6514500Sep 7, 2000Feb 4, 2003Conjuchem, Inc.Long lasting synthetic glucagon like peptide {GLP-!}US6528486Jul 12, 2000Mar 4, 2003Zealand Pharma A/SPeptide agonists of GLP-1 activityUS6583111Jun 1, 2000Jun 24, 2003Eli Lilly And CompanyUse of GLP-1 analogs and derivative adminstered peripherally in regulation of obesityUS6593295Jun 6, 2001Jul 15, 2003Conjuchem, Inc.Long lasting insulinotropic peptidesUS6602981Mar 1, 2001Aug 5, 2003Conjuchem, Inc.Antinociceptive agent derivativeUS6610825Mar 1, 2001Aug 26, 2003Conjuchem, Inc.Method for alleviating pain or providing an analgesic effect in a patientUS6660716Jun 6, 2000Dec 9, 2003Eli Lilly And CompanyMethod for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereofUS6703359Feb 5, 1999Mar 9, 2004Amylin Pharmaceuticals, Inc.Inotropic and diuretic effects of exendin and GLP-1US6706689May 18, 2001Mar 16, 2004Amylin Pharmaceuticals, Inc.Treatment of acute coronary syndrome with GLP-1US6706892Sep 6, 2000Mar 16, 2004Conjuchem, Inc.Pulmonary delivery for bioconjugationUS6723530Feb 5, 1998Apr 20, 2004Amylin Pharmaceuticals, Inc.Polynucleotides encoding proexendin, and methods and uses thereofUS6767887Jun 5, 1997Jul 27, 2004Roche Diagnostics GmbhExendin analogues, processes for their preparation and medicaments containing themUS6821949Nov 4, 2002Nov 23, 2004Conjuchem, Inc.Long lasting synthetic glucagon-like peptide (GLP-1)US6849714May 17, 2000Feb 1, 2005Conjuchem, Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood componentsUS6858576Aug 8, 1997Feb 22, 2005Amylin Pharmaceuticals, Inc.Methods for regulating gastrointestinal motilityUS6861236Feb 7, 2003Mar 1, 2005Applied Nanosystems B.V.Export and modification of (poly)peptides in the lantibiotic wayUS6872700Jan 14, 2000Mar 29, 2005Amylin Pharmaceuticals, Inc.Methods for glucagon suppressionUS6887470Sep 7, 2000May 3, 2005Conjuchem, Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood componentsUS6887849Nov 4, 2002May 3, 2005Conjuchem, Inc.Long lasting synthetic glucagon-like peptide {GLP-1}US6894024Oct 22, 2001May 17, 2005Amylin Pharmaceuticals, Inc.Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptideUS6902744Jan 14, 2000Jun 7, 2005Amylin Pharmaceuticals, Inc.Exendin agonist formulations and methods of administration thereofUS6924264Apr 28, 2000Aug 2, 2005Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonistsUS6956026Jan 7, 1998Oct 18, 2005Amylin Pharmaceuticals, Inc.Use of exendins for the reduction of food intakeUS6989366Jun 28, 2002Jan 24, 2006Amylin Pharmaceuticals, Inc.Exendins, exendin agonists, and methods for their useUS6998387Mar 16, 1999Feb 14, 2006Amylin Pharmaceuticals, Inc.Human appetite control by glucagon-like peptide receptor binding compoundsUS7090851Sep 7, 2000Aug 15, 2006Conjuchem Inc.Long lasting fusion peptide inhibitors of viral infectionUS7105490Jul 30, 2003Sep 12, 2006Amylin Pharmaceuticals, Inc.Methods and compositions for treating polycystic ovary syndromeUS7112567Feb 15, 2002Sep 26, 2006Conjuchem Inc.Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disordersUS7115569Oct 15, 2004Oct 3, 2006Amylin Pharmaceuticals, Inc.Exendins, exendin agonists, and methods for their useUS7138375Oct 14, 2004Nov 21, 2006Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for lowering plasma lipidUS7144854Sep 7, 2000Dec 5, 2006Conjuchem, Inc.Long lasting anti-angiogenic peptidesUS7157555Aug 6, 1998Jan 2, 2007Amylin Pharmaceuticals, Inc.Exendin agonist compoundsUS7166695Sep 2, 2004Jan 23, 2007Conjuchem Biotechnologies Inc.Affinity markers for human serum albuminUS7223725Nov 13, 1998May 29, 2007Amylin Pharmaceuticals, Inc.Exendin agonist compoundsUS7226990Jun 21, 2001Jun 5, 2007Novo Nordisk A/SExtendin derivativesUS7256253Feb 25, 2005Aug 14, 2007Conjuchem Biotechnologies Inc.Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood componentsUS7268113Feb 1, 2002Sep 11, 2007Conjuchem Biotechnologies Inc.Long lasting growth hormone releasing factor derivativesUS7297761Jul 19, 2004Nov 20, 2007Amylin Pharmaceuticals, Inc.Pharmaceutical compositions containing exendinsUS7307148Apr 22, 2005Dec 11, 2007Conjuchem Biotechnologies Inc.Method for purification of albumin conjugatesUS7419952Mar 3, 2006Sep 2, 2008Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof to treat diabetesUS20010047084Jun 21, 2001Nov 29, 2001Knudsen Liselotte BjerreExtendin derivativesUS20030170250May 20, 2002Sep 11, 2003Ezrin Alan M.Local delivery of long lasting therapeutic agentsUS20040053819Dec 7, 2001Mar 18, 2004Dodd Steven WittChronic treatment regimen using glucagon-like insulinotropic peptidesUS20040127398Nov 25, 2003Jul 1, 2004Conjuchem, Inc.Long lasting synthetic glucagon like peptide (GLP-1)US20040138100Nov 25, 2003Jul 15, 2004Conjuchem, Inc.Long lasting synthetic glucagon like peptide (GLP-1)US20040156859Jan 12, 2004Aug 12, 2004Conjuchem, Inc.Pulmonary delivery for bioconjugationUS20040266673Jul 29, 2003Dec 30, 2004Peter BakisLong lasting natriuretic peptide derivativesUS20050065075May 31, 2002Mar 24, 2005Erickson John W.Long lasting fusion peptide inhibitors for hiv infectionUS20050070475Sep 24, 2004Mar 31, 2005Conjuchem, Inc.Long lasting fusion peptide inhibitors of viral infectionUS20050176641Jan 21, 2005Aug 11, 2005Conjuchem, Inc.Long lasting natriuretic peptide derivativesUS20050176643Feb 25, 2005Aug 11, 2005Conjuchem, Inc.Anti-obesity agentsUS20060009377Jun 29, 2005Jan 12, 2006Conjuchem, Inc.Long lasting synthetic glucagon like peptide (GLP-1)US20060069029Nov 10, 2005Mar 30, 2006Kolterman Orville GExendin analog formulationsUS20060135426Dec 14, 2005Jun 22, 2006Conjuchem, Inc.Long lasting synthetic glucagon like peptide (GLP-1)US20060135428Feb 8, 2006Jun 22, 2006Bridon Dominique PLong lasting anti-angiogenic peptidesUS20060217304Dec 23, 2005Sep 28, 2006Bridon Dominique PLong lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disordersUS20060241019Jul 26, 2004Oct 26, 2006Bridon Dominique PLong lasting insulin derivatives and methods thereofUS20070207958Nov 9, 2006Sep 6, 2007Bridon Dominique PMethod of treatment of diabetes and/or obesity with reduced nausea side effectUS20070269863Dec 22, 2006Nov 22, 2007Bridon Dominique PProcess for the production of preformed conjugates of albumin and a therapeutic agentUS20090075890Aug 1, 2008Mar 19, 2009Conjuchem Biotechnologies Inc.Long lasting synthetic exendin-4 peptide conjugates and methods of use thereofUS20090093408Aug 1, 2008Apr 9, 2009Bridon Dominique PProtection of exendin-4 peptides through conjugationUS20090175821Oct 31, 2007Jul 9, 2009Bridon Dominique PModified therapeutic peptides with extended half-lives in vivoUS20090186819Dec 11, 2008Jul 23, 2009Marieve CarrierFormulation of insulinotropic peptide conjugatesEP0204447A2May 14, 1986Dec 10, 1986Eye Research Institute Of Retina FoundationPharmaceutical preparations which may be used for stimulating tear secretionEP0602290B1Dec 4, 1992Aug 25, 1999ConjuChem, Inc.Antibody-conjugated Hepatitis B surface antigen and use thereofEP0969016A2Apr 14, 1993Jan 5, 2000Scios Inc.Glucagon-like peptide and insulinotropin derivatesEP0996459B1Jan 7, 1998Sep 21, 2005Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the reduction of food intakeEP1133312B1Jun 6, 2000Sep 12, 2007Eli Lilly And CompanySynergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetesEP1140145B1Jan 14, 2000Jul 6, 2005Amylin Pharmaceuticals, Inc.Novel exendin agonist formulations and methods of administration thereofEP1175443A1Apr 28, 2000Jan 30, 2002Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonistsEP1390061A2Dec 7, 2001Feb 25, 2004Eli Lilly And CompanyChronic treatment regimen using glucagon-like insulinotropic peptidesWO1989010134A1Apr 14, 1989Nov 2, 1989The Regents Of The University Of CaliforniaChimeric peptides for neuropeptide delivery through the blood-brain barrierWO1996029342A1Mar 18, 1996Sep 26, 1996Novo Nordisk A/SLipophilic peptide hormone derivativesWO1996039128A1Jun 4, 1996Dec 12, 1996Hemosphere, Inc.Protein particles for therapeutic and diagnostic useWO1997046584A1Jun 5, 1997Dec 11, 1997Boehringer Mannheim GmbhExendin analogues, processes for their preparation and medicaments containing themWO1998039022A1Mar 3, 1998Sep 11, 19981149336 Ontario Inc.Methods of using exendin and glp-1, and agonists and antagonists thereof, to affect the central nervous systemWO1999043708A1Feb 25, 1999Sep 2, 1999Novo Nordisk A/SGlp-1 derivatives of glp-1 and exendin with protracted profile of actionNon-Patent CitationsReference14th Petition to Accept an Unintentionally Delayed Claim for Priority Under 37 C.F.R. § 1.78 (A)(3) with accompanied exhibits, and Petition under 37 C.F.R. § 1.182 to request expedite review of petition under 37 C.F.R. § 1.78 (A)(3), filed with the U.S. Patent and Trademark Office on May 13, 2010, for U.S. Appl. No. 10/722,733, 29 pages.25th Renewed Petition Under 37 C.F.R. § 1.78 (A)(3), and Petition under 37 C.F.R. § 1.182 to Request Expedite Review of Petition under 37 C.F.R. § 1.78 (A)(3), filed with the U.S. Patent and Trademark Office on Aug. 3, 2010, for U.S. Appl. No. 10/722,733, 10 pages.3Action Closing Prosecution, dated Mar. 5, 2009, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.4Akil, H. et al. (1984) "Endogenous Opioids: Biology and Function," Ann. Rev. Neurosci., 7: 223-255.5Amendment and Response Pursuant to 37 C.F.R. § 1.195(a), dated May 5, 2009, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.6Ateshkadi et al., 1993, "Pharmacokinetics of Intraperitoneal, Intravenous, and Subcutaneous Recombinant Human Erythropoietin in Patients on Continuous Ambulatory Peritoneal Dialysis," Am. J. Kidney Dis. 21(6):635-642.7Barragan, Jose M. et al. (1996) "Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats," Regulatory Peptides, 67:63-68.8Bell, G.J. et al. (1983) "Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides," Nature, 302: 716-718.9Benhar, Itai et al. (1994) "Pseudomonas Exotoxin A Mutants," J. of Biological Chem. 269(18), pp. 13398-13404.10Bergmann, Pierre J. et al. (1985) "Cationized Serum Albumin Enhances Response of Cultured Fetal Rat Long Bones to Parathyroid Hormone," Endocrinology, 116(5), pp. 1729-1733.11Bhargava, Kumaril et al. (1992) "Immobilization of Active Urokinase on Albumin Microspheres: Use of a Chemical Dehydrant and Process Monitoring," Pharmaceutical Research 9(6), pp. 776-781.12Binder et al., 1984, "Insulin Pharmacokinetics," Diabetes Care 7:188-199.13Breton, Jerome et al. (1995) "Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin," Eur. J. Biochem., 231: 563-569.14Coleman, 1978, "Obese and Diabetes: Two Mutant Genes Causing Diabetes-Obesity Syndromes in Mice," Diabetologia 14:141-148.15Comments on Petition Under 37 C.F.R. § 1.182 Requesting Continued Reexamination, dated Feb. 4, 2010, for Reexamination Request Control No. 95/000,276.16Comments on Petition under 37 C.F.R. § 1.182 Requesting Continued Reexamination, dated Feb. 4, 2010, for U.S. Patent No. 6,924,261 B1, Reexamination Request Control No. 95/000,276, 46 pages.17Comments Pursuant to 37 C.F.R. § 1.947 by Third Party Request, dated Apr. 14, 2010, for U.S. Patent No. 6,924,261 B1, Reexamination Request Control No. 95/000,276, 50 pages.18Comments Pursuant to 37 C.F.R. § 1.947 by Third Party Requester, dated May 15, 2008, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.19Comments Pursuant to 37 C.F.R. § 1.951(b) by Third Party Requester, dated Jun. 3, 2009, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.20Comments Pursuant to 37 CFR 1.947 by Third Party Requester to Patent Owner's Amendment and Response Filed May 5, 2009, dated Apr. 14, 2010, for Reexamination Request Control No. 95/000,276.21Davis et al., 1991, "Reduction of Immunogenicity and Extension of Circulating Half-Life of Peptides and Proteins," Peptide and Protein and Drug Delivery, Marcel Dekker, Inc., New York, 831-864.22Decision on 4th Renewed Petition Under 37 C.F.R. § 1.78 (A)(3), and Petition under 37 C.F.R. § 1.182, mailed Jun. 10, 2010, for U.S. Appl. No. 10/722,733, 3 pages.23Decision on First Request for Reconsideration of Decision on Petition Under 37 C.F.R. § 1.182, dated Dec. 19, 2008, for U.S. Appl. No. 10/722,733, 2 pages.24Decision on Petition to Continue Inter Partes Reexamination Proceedings, dated Mar. 16, 2010, for Reexamination Request Control No. 95/000,276.25Decision on Petition Under 37 C.F.R. § 1.182, Requesting Entry of an Application Data Sheet (ADS), dated Sep. 2, 2008, for U.S. Appl. No. 10/722,733, 2 pages.26Decision on Renewed Petition Under 37 C.F.R. § 1.78 (A)(3), and Petition under 37 C.F.R. § 1.182, mailed Sep. 10, 2010, for U.S. Appl. No. 10/722,733, 6 pages.27Decision on Second Request for Reconsideration of Decision on Petition Under 37 C.F.R. § 1.182, dated May 19, 2009, for U.S. Appl. No. 10/722,733, 3 pages.28Decision on Third Request for Reconsideration of Decision on Petition Under 37 C.F.R. § 1.182, dated Mar. 15, 2010, for U.S. Appl. No. 10/722,733, 4 pages.29Declaration of Andrew Young, M.D., Ph.D., Pursuant to 37 C.F.R. § 1.132, dated Apr. 15, 2008, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.30Declaration of John Eng, M.D., Pursuant to 37 C.F.R. § 1.132, dated Apr. 23, 2009, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.31Declaration of John Herich Pursuant to 37 C.F.R. § 1.132, dated Apr. 15, 2008, for Reexamination of Prickett et al U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.32Declaration of Mark J. Poznansky. dated Jul. 6, 2007, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.33Declaration of Omar Quraishi, dated Jul. 6, 2007, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.34Declaration of Rüdiger Göke and Burkhard Güke, Pursuant to 37 C.F.R. § 1.132, dated May 2, 2009, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.35Delgado, Christina et al. (1992) "The Uses and Properties of PEG-Linked Proteins," Critical Reviews in Therapeutic Drug Carrier Systems 9(3,4), pp. 249-304.36Drucker, Daniel J. (Feb. 1998) "Glucagon-Like Peptides," Diabetes, 47(2):159-169.37Edwards, C. Mark B. et al. (1999) "Glucagon-Like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans," Diabetes 48, pp. 86-93.38Edwards, C. Mark B. et al. (2001) "Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Volunteers," Am. J. Physiol. Endocrinol. Metab 281, pp. E155-E161.39Eng et al. (1992) "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspectum Venom," J. of Biological Chemistry 267(11), pp. 7402-7405.40Eng et al., 1990, "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from Heloderma horridumVenom," J. Biol. Chem. 265:20259-20262.41Eng, John (1996) "Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice," Diabetes, 45:152A (abstract 554).42Ex Parte Quayle mailed Dec. 31, 2008, for U.S. Appl. No. 11/170,967, filed Jun. 29, 2005, 4 pages.43Ex Parte Quayle mailed Dec. 31, 2008, for U.S. Appl. No. 11/304,446, filed Dec. 14, 2005, 4 pages.44Ex Parte Quayle mailed Sep. 10, 2008, for U.S. Appl. No. 11/170,967, filed Jun. 29, 2005, 6 pages.45Ex Parte Quayle mailed Sep. 10, 2008, for U.S. Appl. No. 11/304,446, filed Dec. 14, 2005, 6 pages.46Final Office Action mailed Dec. 7, 2009, for U.S. Appl. No. 11/170,967, filed Jun. 29, 2005, 7 pages.47Final Office Action mailed Dec. 7, 2009, for U.S. Appl. No. 11/304,446, filed Dec. 14, 2005, 7 pages.48Final Office Action mailed Feb. 7, 2011, for U.S. Appl. No. 12/221,553, filed Aug. 1, 2008, 9 pages.49Final Office Action mailed Jun. 28, 2010, for U.S. Appl. No. 11/304,446, filed Dec. 14, 2005, 7 pages.50Final Office Action mailed Jun. 29, 2010, for U.S. Appl. No. 11/170,967, filed Jun. 29, 2005, 7 pages.51Final Office Action mailed Mar. 26, 2008, for U.S. Appl. No. 11/170,967, filed Jun. 29, 2005, 8 pages.52Final Office Action mailed Mar. 26, 2008, for U.S. Appl. No. 11/304,446, filed Dec. 14, 2005, 9 pages.53First Request for Reconsideration of Decision on Petition Under 37 C.F.R. § 1.182, dated Oct. 30, 2008, for U.S. Appl. No. 10/722,733, 4 pages.54Foa, Piero P. et al. (1991) "Glucagon and Other Products of the Proglucagon Gene: Physiology and Possible Role in the Pathogenesis of Disease," Giornale Italiano Di Diabetologia 11: (Supplemental) pp. 1-41.55Francis, G. E. et al. (1998) "PEGylation of Cytokines and other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques," International Journal of Hematology 68, pp. 1-18.56Göke et al., 1989, "Characterization of the Receptor for Glucagon-like-peptide-1(7-36)amide on Plasma Membranes from Rat Insulinoma-derived Cells by Covalent Cross-Linking," J. Mol. Endocrinol. 2:93-98.57Göke et al., 1992, "Solubilization of Active GLP-1 (7-36)amide Receptors From RINm5F Plasma Membranes," FEBS Lett. 300:232-236.58Göke et al., 1993, "Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting beta-Cells," J. Biol. Chem. 268(26):19650-19655.59Göke et al., 1993, "Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells," J. Biol. Chem. 268(26):19650-19655.60Göke et al., 1995, "Distribution of GLP-1 Binding Sites in the Rat Brain: Evidence that Exendin-4 is a Ligand of Brain GLP-1 Binding Sites," Eur. J. Neurosci. 7:2294-2300.61Gombotz, Wayne R. et al. (1995) "Biodegradable Polymers for Protein and Peptide Drug Delivery," Bioconjugate Chem. 6, pp. 332-351.62Goodson, Robert J. et al. (1990) "Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site," Bio/Technology 8, pp. 343-346.63Goosen, Mattheus F. A. (1985) "Optimization of Microencapsulation Parameters: Semipermeable Microcapsules as a Bioartificial Pancreas," Biotechnology and Bioengineering vol. XXVII, pp. 146-150.64Grieg et al., Jan. 1999, "Once Daily Injection of Exendin-4 to Diabetic Mice Achieves Long-Term Beneficial Effects of Blood Glucose Concentrations," Diabetologia 42:45-50.65Haak, 1999, "New Developments in the Treatment of Type I Diabetes Mellitus," Exp. Clin. Endocrinol. Diabetes 107(Supp. 3):S108-113.66Harlow & Lane, 1988, .Antibodies:A Laboratory Manual, pp. 101, 129.67Heinrich, G. et al, (1984) "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," Endocrinology, 115: 2176-2181.68Hirai, Y. et al. (1979) "A new mast cell degranuleting peptide "mastoperan" in the venom of Vespula levvisii," Chem. Pharm. Bull., 27(8): 1942-1944.69Hoshino et al., 1984, "Primary Structure of Helodermin, a VIP-Secretin-Like Peptide Isolated from Gila Monster Venom," FEBS Lett. 178:233-239.70Hupe-Sodmann, Karin et al. (1997) "Endoproteolysis of Glucagon-like Peptide (GLP)-1 (7-36) amide by Ectopeptidases in RINm5F Cells," Peptides, 18(5):625-632.71Ishikawa, E. et al. (Oct. 7, 1978) "Enzyme-Labeling with Maleimides and Its Application to the Immunoassey of Peptide Hormones," Enzyme Labeled Immunoassay of Hormones and Drugs, Walter deGruyter& Co.., Berlin, New York, pp. 43-57.72Isoai, Atsushi et al. (1993) "A Potent Anti-Metastatic Activity of Tumor Invasion-Inhibiting Factor-2 and Albumin Conjugate," Biochemical and Biophysical Research Communications 192(1), pp. 7-14.73Kapas, S. et al. (1995) "Cloning and Expression of cDNA Encoding a Rat Adrenomedullin Receptor," J. Biol. Chem., 270(43): 25344-25347.74Kelly et al., 1996, "Acute Effects of Intraperitoneal Versus Subcutaneous Insulin Delivery on Glucose Homeostasis in Patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group," Diabetes Care 11:1237-1242.75Knusli, C. et al. (1992) "Polyethylene glycol (PEG) modification of granulocyte macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity," British Journal of Haematology, 82: 654-663.76Kolodny, Nelly et al. (1990) "A Conjugation of Synthetic Peptides to Proteins: Quantitation from S-Carboxymethylcysteine Released upon Acid Hydrolysis," Analytical Biochemistry 187, pp. 136-140.77Lopez, L.C. at al. (1983) "Mammalian Pancreatic Preproglucagon Contains three Glucagon-related Peptides," Proc. Natl. Acad. Sci. USA, 80: 5485-5489.78Mao, G. D. et al. (1989) "Superoxide Dismutase: Improving Its Pharmacological Properties by Conjugation with Human Serum Albumin," Biomat., Art. Cells, Art. Org., 17(3), pp. 229-244.79Marburg et al. (1996) "Introduction of the Maleimide Function onto Resin-Bound Peptides: A simple, High yield Process Useful for discriminating among Several Lysines." Bioconjugate Chemistry, 7; 612-616.80Mattson et al., 1993, "A Practical Approach to Crosslinking," Mol. Biol. Reports 17:167-183.81Meurer et al. (1999) "Properties of Native and in Vitro Glycosylated Forms of the Glucagon-Like Peptide-1 Receptor Antagonist Exendin (9-39)," Metabolism 48(6), pp. 716-724.82Motteson, Kenneth et al., Proceedings of the 8th American Peptide Symposium, 1983, pp. 409-412.83Mumby, S.M. et al. 1986 "Antisera of designed specificity for subunits of guanine nucleotide-binding regulatory," Proc. Natl. Acad. Sci., 83:265-269.84Non-final Office Action mailed Jun. 26, 2007, for U.S. Appl. No. 11/170,967, filed Jun. 29, 2005, 11 pages.85Non-final Office Action mailed Jun. 26, 2007, for U.S. Appl. No. 11/304,446, filed Dec. 14, 2005, 13 pages.86Non-final Office Action mailed May 18, 2010, for U.S. Appl. No. 12/221,553, filed Aug. 1, 2008, 14 pages.87Non-final Office Action mailed May 22, 2009, for U.S. Appl. No. 11/170,967, filed Jun. 29, 2005, 7 pages.88Non-final Office Action mailed May 22, 2009, for U.S. Appl. No. 11/304,446, filed Dec. 14, 2005, 6 pages.89Non-final Office Action, dated Jan. 17, 2008, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.90Notice of Appeal Pursuant to 37 C.F.R. § 41.61 (a)(I), dated Jan. 6, 2010, for U.S. Patent No. 6,924,261 B1, Reexamination Request Control No. 95/000,276, 2 pages.91Order Granting Request for Inter Partes Reexamination, dated Oct. 3, 2007, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.92Oren, Z. et al. (1998) "Mode of Acyion of Linear Amphipathic alpha-Helical antimicrobial Peptides," Biopolymers (Peptide Science), 47: 451-463.93Oren, Z. et al. (1998) "Mode of Acyion of Linear Amphipathic α-Helical antimicrobial Peptides," Biopolymers (Peptide Science), 47: 451-463.94Paige et al., 1995, "Prolonged Circulation of Recombinant Human Granulocyte-Colony Stimulating Factor by Covalent Linkage to Albumin Through a Heterobifunctional Polyethylene Glycol," Pharmaceutical Research 12(12):1883-1888.95Patrias, Karen et al., Biotech Report, 1994/1995, pp. 106-107.96Petition Under 37 C.F.R. § 1.182 Requesting Continued Reexamination, dated Jan. 6, 2010, for Reexamination Request Control No. 95/000,276.97Petition Under 37 C.F.R. § 1.182, Requesting Entry of an Application Data Sheet (ADS), dated Jun. 30, 2008, for U.S. Appl. No. 10/722,733, 30 pages.98Petrella et al., May 1999, "Development and Validation of an Immunoradiometric Assay (IRMA) for the Quantitation of Exendin-4 in Plasma and Its Application to Preclinical Toxicity and Phase I Clinical Evaluations," Diabetes 48:A425.99Pohl, M. et al. (Apr. 17, 1998). "Molecular Cloning of the Helodermin and Exendin-4 cDNAs in the Lizard: Relationship to Vasoactive Intestinal Polypeptide/Pituitary Adenylate Cyclase Activating Polypeptide and Glucagon-Like Peptide 1 and Evidence Against the Existence of Mammalian Homologues," Journal of Biological Chemistry 273(16):9778-9784.100Poznansky & Juliano, 1984, "Biological Approaches to the Controlled Delivery of Drugs: A Critical Review," Pharmacological Reviews 36:277-335.101Poznansky, Mark J. et al. (1988) "Growth Hormone-Albumin Conjugates Reduced Renal Toxicity and Altered Plasma Clearance," FEBS Letters 239(1), pp. 18-22.102Qu, Daqing et al. (1996) "A Role for Melanin-Concentrating Hormone in the Central Regulation of Feeding Behaviour," Nature (380), pp. 243-247.103Raufman, Jean-Pierre (1996) "Bioactive peptides from lizard venoms," Regulatory Peptides, 61:1-18.104Request for Inter Partes Reexamination Pursuant to 35 U.S.C. § 311 and 37 C.F.R. 1.913, dated Jul. 9, 2007, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.105Response Pursuant to 35 U.S.C. § 304 and 37 C.F.R. 1.111, dated Apr. 16, 2008. for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.106Response Pursuant to 37 C.F.R. § 1.951(a), dated Apr. 18, 2011, for U.S. Patent No. 6,924,261 B1, Reexamination Request Control No. 95/000,276, 12 pages.107Reubi, J.C. et al. (1982) "Specific High Affinity Binding Sites for Somatostatin-28 on Pancreatic beta-Cells: Differences with Brain Somatostatin Receptors," Endocrinology, 110(3):1049-4051.108Reubi, J.C. et al. (1982) "Specific High Affinity Binding Sites for Somatostatin-28 on Pancreatic β-Cells: Differences with Brain Somatostatin Receptors," Endocrinology, 110(3):1049-4051.109Richter et al., 1991, "Characterization of Glucagon-Like Peptide-I(7-36)amide Receptors of Rat Lung Membranes by Covalent Cross-Linking," FEBS Lett. 280:247-250.110Right of Appeal Notice (37 C.P.R. § 1.953) , dated Dec. 17, 2009, for Reexamination Request Control No. 95/000,276.111Ringsdorf, Helmut (1975) "Structure and Properties of Pharmacologically Active Polymers," J. Polymer Sci: Symposium No. 51, pp. 135-153.112Ritzel, U. et al. (1998) "A synthetic glucagon-like peptide-1 analog with improved plasma stability," Journal of Endocrinology, 159:93-102.113Robberecht, Patrick et al. (1985) "Immunoreactive Helodermin-Like Peptides in Rat: A New Class of Mammalian Neuropeptides Related to Secretin and VIP," Biochemical and Biophysical Research Communications 130(1), pp. 333-342.114Ruiz-Grande, Carmen et al. (1992) "Lipolytic Action of Glucagon-Like Peptides in Isolated Rat Adipocytes," Peptides (13), pp. 13-16.115Santiago, Julio V. ed. (1996). Diabetes. Abstract Book. 56th Annual Meeting and Scientific Sessions, Saturday, Jun. 6-Tuesday Jun. 11, 1996, San Francisco, California. Abstracts 553-556.116Schirra, Jorg et al. (Apr. 1998) "Exendin(9-39)amide is an Antagonist of Glucagon-like Peptide-1(7-36)amide in Humans," J. Clin. Invest., 101(7):1421-1430.117Schmidtler et al., 1994, "Rat Parietal Cell Receptors for GLP-1-(7-36) Amide: Northern Blot, Cross-Linking, and Radioligand Binding," Am. J. Physiol. 267:G423-432.118Second Declaration of John Herich Pursuant to 37 C.F.R. § 1.132, dated Apr. 30, 2009, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.119Second Declaration of Mark J. Poznansky, dated Jul. 6, 2007, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.120Second Declaration of Omar Quraishi, dated May 15, 2008, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.121Second Request for Reconsideration of Decision on Petition Under 37 C.F.R. § 1.182, dated Feb. 5, 2009, for U.S. Appl. No. 10/722,733, 7 pages.122Selkoe, D.J. (1993) "Physiological production of the beta-amyloid protein and the mechanism of Alzhelmer's disease," TINS, 16(10): 403-409.123Selkoe, D.J. (1993) "Physiological production of the β-amyloid protein and the mechanism of Alzhelmer's disease," TINS, 16(10): 403-409.124Siegel et al. (1999) "Biological Activity of GLP-1 analogues with N-terminal modifications," Regulatory Peptides. 79(23):93-102.125Smith, F.G. et al. (1989) "Atrial natriuretic factor during fetal and postnatal life: A review," J. Dev. Physiol., 12:55-62.126Stehle. G. et al. (1997) "The Loading Rate Determines Tumor Targeting Properties of Methotraxate-Albumin Conjugates in Rats " Anti-Cancer Drugs, 8: 677-685.127Syed, Summer et al. (May 1997) "Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin," Blood, 89(9):3243-3252.128Thibaudeau et al., 2006, "CJC-1134-PC: An Exendin-4 Conjugate with Extended Pharmacodynamic Profiles in Rodents," American Diabetes Association 66th Scientific Sessions, Washington D.C., Jun. 9-13, 2006 (poster 434-P).129Thim, L. et al. (1998) "Molecules in focus; CART, a new.anorectic peptide," Int. J. Biochem. Cell. Biol., 30:1281-1284.130Thim, L. et al. (1998) "Molecules in focus; CART, a new•anorectic peptide," Int. J. Biochem. Cell. Biol., 30:1281-1284.131Third Declaration of Mark J. Poznansky, dated May 14, 2008, for Reexamination of Prickett et al., U.S. Patent No. 6,924,264 B1, Reexamination Request Control No. 95/000,276.132Third Party Comments after Patent Owner Response Pursuant to 37 C.F.R. § 1.951, dated May 18, 2011, for U.S. Patent No. 6,924,261 B1, Reexamination Request Control No. 95/000,276, 20 pages.133Third Request for Reconsideration of Decision on Petition Under 37 C.F.R. § 1.182, dated Jul. 16, 2009, for U.S. Appl. No. 10/722,733, 4 pages.134Turton, M.D. et al. (1996) "A Role for Glucagon-Like-Peptide-1 in the Central Regulation of Feeding," Nature (379), pp. 69-72.135U.S. Appl. No. 09/424,571, filed Mar. 7, 2000, Ezrin et al.136U.S. Appl. No. 09/530,891, filed Aug. 16, 2000, Blanchard et al.137U.S. Appl. No. 60/037,412, filed Feb. 5, 1997, Drucker.138U.S. Appl. No. 60/064,705, filed Nov. 7, 1997, Ezrin et al.139U.S. Appl. No. 60/103,498, filed Oct. 8, 1998, Coolidge et al.140U.S. Appl. No. 60/132,018, filed Apr. 30, 1999, Pickett et al.141U.S. Appl. No. 60/152,681, filed Sep. 7, 1999, Ezrin et al.142U.S. Appl. No. 95/000,276, filed Jul. 9, 2007, ConjuChem Biotechnologies Inc.143Vandermeers et al., 1984, "Purification of a Novel Pancreatic Secretory Factor (PSF) and a Novel Peptide with VIP- and Secretin-like Properties (Helodermin) from Gila Monster Venom," FEBS Lett. 166:273-276.144Vandermeers et al., 1987, "Chemical, Immunological and Biological Properties of Peptides Like Vasoactive-Intestinal-Peptide and Peptide-Histidine-Isoleucinamide Extracted from the Venom of Two Lizards (Heloderma horridum and Heloderma suspectum)," Eur. J. Biochem. 164:321-327.145Vilaseca, L. Antonio et al. (1993) "Protein Conjugates of Defined Structure: Synthesis and Use of a New Carrier Molecule," Bioconjugate Chem. 4, pp. 515-520.146Yeh, Patrice et al. (1992) "Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," Proc. Natl. Acad. Sci. USA 89, pp. 1904-1908.147Young, Andrew A. et al. (1999) "Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4," Diabetes 48, pp. 1026-1034.148Zalipsky, Samuel (1995) "Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates," Bioconjugate Chem. 6, pp. 150-165.149Zegers, Netty et al. (1990) "An Improved Conjugation Method for Controlled Covalent Coupling of Synthetic Peptides to Proteins Using Glutaraldehyde in a Dialysis Method," Journal of Immunological Methods 130, pp. 195-200.Classifications U.S. Classification514/1.1, 530/308International ClassificationA61K38/22, A61K38/00, C07K14/16, C07K14/605Cooperative ClassificationA61K38/00, C07K14/005, C07K14/605, C07K14/57563, C12N2740/16122, A61K47/48284European ClassificationA61K38/22, A61K38/26, C07K14/005, C07K14/575L, A61K47/48R2L, C07K14/605Legal EventsDateCodeEventDescriptionMay 24, 2006ASAssignmentOwner name: CONJUCHEM, INC., CANADAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRIDON, DOMINIQUE P.;L ARCHEVEQUE, BENOIT;EZRIN, ALAN M.;AND OTHERS;REEL/FRAME:017667/0865;SIGNING DATES FROM 20000815 TO 20000825Owner name: CONJUCHEM, INC., CANADAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRIDON, DOMINIQUE P.;L ARCHEVEQUE, BENOIT;EZRIN, ALAN M.;AND OTHERS;SIGNING DATES FROM 20000815 TO 20000825;REEL/FRAME:017667/0865Aug 1, 2006ASAssignmentOwner name: CONJUCHEM BIOTECHNOLOGIES INC., CANADAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM INC.;REEL/FRAME:018039/0669Effective date: 20060523Owner name: CONJUCHEM BIOTECHNOLOGIES INC.,CANADAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM INC.;REEL/FRAME:018039/0669Effective date: 20060523Jun 7, 2010ASAssignmentOwner name: CONJUCHEM BIOTECHNOLOGIES INC.,CANADAFree format text: CHANGE OF NAME;ASSIGNOR:4523482 CANADA INC. (CANADIAN CORPORATION NUMBER 4523482);REEL/FRAME:024497/0358Effective date: 20100528Owner name: 4523482 CANADA INC. (CANADIAN CORPORATION NUMBER 4Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC. (CANADIAN CORPORATION NUMBER 6513590);REEL/FRAME:024497/0424Effective date: 20100528Owner name: CONJUCHEM BIOTECHNOLOGIES INC., CANADAFree format text: CHANGE OF NAME;ASSIGNOR:4523482 CANADA INC. (CANADIAN CORPORATION NUMBER 4523482);REEL/FRAME:024497/0358Effective date: 20100528Oct 26, 2010ASAssignmentOwner name: ADVANCED DIAGNOSTICS AND DISCOVERY, CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC.;REEL/FRAME:025198/0735Effective date: 20100823Apr 13, 2011ASAssignmentOwner name: CONJUCHEM, LLC, CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCED DIAGNOSTICS AND DISCOVERY;REEL/FRAME:026122/0692Effective date: 20110218Aug 7, 2015REMIMaintenance fee reminder mailedDec 27, 2015LAPSLapse for failure to pay maintenance feesFeb 16, 2016FPExpired due to failure to pay maintenance feeEffective date: 20151227RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services